Akari net loss widens to $4.81 million in Q2 FY26; operating loss rises to $4.6 million

• Akari Therapeutics posted a GAAP net loss of $4.81 million for the quarter ended June 30, 2026, widening from $1.9 million.
• Operating loss widened to $4.6 million from $3.12 million, while R&D spending rose to $2.08 million from $667,000.
• Cash totaled $7.7 million at June 30, 2026, with management expecting runway into December 2026.
• A $5.2 million May private placement closed; the White Lion $25 million equity line resale registration was declared effective July 7, 2026.
• AKTX-101 GMP manufacturing began with WuXi Biologics/XDC; first-in-human trials targeted for mid-2027, with a July Whitehawk collaboration announced.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037730), on August 13, 2026, and is solely responsible for the information contained therein.